Clinical Trial

A Study of AMC6156 in People With Sarcopenia

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This clinical trial aims to find out whether AMC6156 can improve physical function and is safe in older adults with sarcopenia. Participants will take AMC6156 or a placebo daily for 12 weeks, and their movement, strength, and safety will be regularly monitored through tests and checkups.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-03 -> 2026-10-31 2026-08-04
minor Completion pushed: 2026-06 -> 2027-02-15 2026-08-04
Trial Details
NCT Number NCT07072195
Lead Sponsor Animuscure Inc.
Conditions Sarcopenia in Elderly, Sarcopenia
Enrollment 80 participants
Start Date 2025-07-01
Primary Completion 2026-10-31 (estimated)
Study Completion 2027-02-15 (estimated)
Updated on ClinicalTrials.gov 2026-08-03